1Scagliotti G, Novello S, von Pawel J, et al. Phase Ill study of carboplatin and paclitaxel alone or with sorafenib in advanced non- small-cell lung cancer[J]. J Clin Oncol, 2010, 28(11): 1835-1842.
2Mcdermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group[J]. J Clin Oncol, 2008, 26(13): 2178-2185.
3Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011,364(6): 501-513.
4Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase II study[J]. J Clin Oncol, 2012, 30(9): 921-929.
5Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase Ill , randomized, open-label trial[J]. Clin Breast Cancer, 2011, 11(2): 82-92.
6Barrios CH, Liu MC, Lee SC, et al. Phase ： randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer[J]. Breast Cancer Res Treat, 2010, 121(1): 121-131.
7Gr：ivalos C, Grande E, Gasent JM. The potential role of sunitinib in gastrointestinal cancers other than GIST[J]. Crit Rev Oncol Hematol, 2010, 76(1): 36-43.
8Govidan V, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase 1I trial[J]. J Clin Oncol, 2012, 30(17): 2070-2078.
9Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction[J]. Blood, 2006, 107(11): 4532-4539.
10Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model[J]. Cancer Res, 2008, 68(9): 3323-3333.
二级参考文献20
1Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mor- tality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin O ncol, 2006, 24(14): 2137-2150.
2Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non small celllung cancer: a review of the current evidence. Chest, 2003, 123(Suppl 1) : 137S -146S.
3Herbst RS. Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small- cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol, 2010, 11(7): 619-626.
4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with platinum-basedchemotherapy. J Clin Oncol, 2000,18(10): 2095-2103.
5Fossella FV, DeVore R, Kerr RN~ et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non- small-cell lung cancer previously treated with platinum containing chemo- therapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol, 2000, 18(12): 2354-2362.
6Hanna N, Shepherd FA, Fossella FV~ et al. Randomized phase Ⅲtrial of pemetrexed versus docetaxel in patients with non-small-cell lung can- cer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
7Shepherd FA, Rodrigues PereiraJ, Ciuleanu Tj et al. Erlotinib in Previously treated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
8Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-srnall-cell lung cancer (INTEREST): a randomized phaseⅢ trial. Lancet, 2008, 372(9652): 1809-1818.
9Natale RB, "Ihongprasert S, Greco FA, et al. Phase Ⅲ trial ofvandetanib compared with erlotinib in patients with previously treated advanced non- small-cell lung cancer. J Clin Oncol, 2011, 29(8): 1059-1066.
10Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothe- lial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 2002, 62(16): 4645-46SS.
